[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341301-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341301-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrated-multi-omics-analyses-revealed-the-association-between-rheumatoid-arthritis-and-colorectal-cancer-myo9a-as-a-shared-gene-signature-and-an-immune-related-therapeutic-target","Integrated multi-omics analyses revealed the association between rheumatoid arthritis and colorectal cancer: MYO9A as a shared gene signature and an immune-related therapeutic target","","Study investigates how rheumatoid arthritis (RA) relates to colorectal cancer (CRC), focusing on a shared gene signature and mechanistic links. Causality between RA and CRC is assessed using Mendelian randomization, while summary statistic data-based Mendelian randomization with eQTL supports identification of CRC-related causal genes. Integrated single-cell and bulk RNA sequencing analyzes define shared transcriptional programs and potential pathways, including prediction of shared hub gene performance in CRC immunotherapy response. Pan-cancer profiling examines MYO9A across 33 tumor types.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrated-multi-omics-analyses-revealed-the-association-between-rheumatoid-arthritis-and-colorectal-cancer-myo9a-as-a-shared-gene-signature-and-an-immune-related-therapeutic-target/341301/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrated-multi-omics-analyses-revealed-the-association-between-rheumatoid-arthritis-and-colorectal-cancer-myo9a-as-a-shared-gene-signature-and-an-immune-related-therapeutic-target/341301.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research question about RA and CRC?","Question",{"text":63,"@type":64},"The study explores the relationship between rheumatoid arthritis and colorectal cancer, including a shared gene signature and underlying mechanisms connecting the two diseases.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was causality between RA and CRC evaluated?",{"text":68,"@type":64},"Causality was assessed using Mendelian randomization (MR) analysis, with summary statistic data-based MR leveraging eQTL data (SMR) to identify CRC-related causal genes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which gene is highlighted as a shared signature and therapeutic target?",{"text":72,"@type":64},"MYO9A is identified as a causal gene and a shared gene signature in both RA and CRC, with implications for immune-related therapeutic targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341301,1790193899,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Zhan et al. BMC Cancer (2024) 24:714 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12466-5](https://doi.org/10.1186/s12885-024-12466-5)  \nRESEARCH Open Access  \nIntegrated multi-omics analyses revealed the  association between rheumatoid arthritis and colorectal cancer: MYO9A as a shared  \ngene signature and an immune-related therapeutic target  \nZhi-Qing Zhan 1,2†, Ze-Min Huang3†, Qi-Wen Lan3†, Yu-Hua Luo3†, Jia-Xin Li4, Ya-Fang Zheng3, Ying-Zhou Chen4, Pei-Zhen Chen3, Tian-Ye Luo3, Baoqing Sun 1* and Zhangkai J Cheng 1*  \nAbstract  \nBackground Our study aims to explore the relationship, shared gene signature, and the underlying mechanisms that connect rheumatoid arthritis (RA) to colorectal cancer (CRC) .  \nMethods Mendelian randomization (MR) analysis was conducted to assess the causality between RA and CRC. Summary statistic data-based Mendelian randomization (SMR) leveraging eQTL data was employed to identify the CRC-related causal genes. Integrated analyses of single-cell RNA sequencing and bulk RNA sequencing were employed to comprehensively investigate the shared gene signature and potential mechanisms underlying the pathogenesis of both RA and CRC. Predictive analysis of the shared hub gene in CRC immunotherapy response was performed. Pan-cancer analyses were conducted to explore the potential role of MYO9A in 33 types of human tumors. Results MR analysis suggested that RA might be associated with a slight increased risk of CRC (Odds Ratio = 1 . 04, 95% Confidence Interval = 1 .01–1. 07, P = 0 . 005) . SMR analysis combining transcriptome analyses identified MYO9A asa causal gene in CRC and a shared gene signature in both RA and CRC. MYO9A may contribute to tumor suppression, while downregulation of MYO9A may impact CRC tumorigenesis by disrupting epithelial polarity and architecture, resulting in a worse prognosis in CRC. Additionally, MYO9A shows promise as a powerful predictive biomarker for cancer prognosis and immunotherapy response in CRC. Pan-cancer analyses demonstrated MYO9A may have a protective role in the occurrence and progression of various human cancers.  \n†Zhi-Qing Zhan, Ze-Min Huang, Qi-Wen Lan andYu-Hua Luo contributed equally to this work and should be considered co-first authors  \n*Correspondence: Baoqing Sun [sunbaoqing@vip.163.com](sunbaoqing@vip.163.com)[ ](sunbaoqing@vip.163.com)Zhangkai J Cheng [jasontable@gmail.com](jasontable@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nZhan et al. BMC Cancer (2024) 24:714 Page 2 of 16  \nConclusion RA might be associated with a slight increased risk of CRC. MYO9A is a shared gene signature and a potential immune-related therapeutic target for both CRC and RA. Targeting the MYO9A-mediated loss of polarity and epithelial architecture could be a novel therapeutic approa","cbCaifGhdlihThR8","https://ap.wps.com/l/cbCaifGhdlihThR8","pdf",5536330,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the main research question about RA and CRC?\",\"answer\":\"The study explores the relationship between rheumatoid arthritis and colorectal cancer, including a shared gene signature and underlying mechanisms connecting the two diseases.\"},{\"question\":\"How was causality between RA and CRC evaluated?\",\"answer\":\"Causality was assessed using Mendelian randomization (MR) analysis, with summary statistic data-based MR leveraging eQTL data (SMR) to identify CRC-related causal genes.\"},{\"question\":\"Which gene is highlighted as a shared signature and therapeutic target?\",\"answer\":\"MYO9A is identified as a causal gene and a shared gene signature in both RA and CRC, with implications for immune-related therapeutic targeting.\"}]","Integrated multi-omics analyses revealed the association between rheumatoid arthritis and colorectal cancer: MYO9A as a shared gene signature and an immune-related therapeutic target | PDF",1790041426,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91a492554cee8d18a250b08dc217edc5.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/509591d096ede6becbca16fc3e8f68b7.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3cf36d83b01eee78bd61e8ddf187271.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00844d7fa11d4d4476be3a452ac8f571.webp",980,1306]